CALABRESI L.

The molecular bases of hypoalphalipoproteinemia (HA), which is associated with premature coronary heart disease (pCAD) in most cases, were investigated in 80 Italian probands. ABCA1, Apo AI, LCAT, LPL and GBA were the candidate genes. The molecular defect was found in 64% of probands (4% ABCA1, 4% Apo AI, 11% LCAT, 44% LPL and 1% GBA...

Background and aims: Cholesteryl ester storage disease (CESD) due to LIPA gene mutations is characterized by hepatic steatosis, hypercholesterolemia and hypoalphalipoproteinemia, exposing affected patients to an increased cardiovascular risk. Further insights into the impact of LIPA gene mutations on lipid/lipoprotein metabolism are limited....

IntroductionLomitapide is a microsomal triglyceride transfer protein inhibitor for patients with homozygous familial hypercholesterolaemia. Due to its mechanism of action, potential hepatic effects of lomitapide are of clinical interest. This study aimed to determine the long-term hepatic safety of lomitapide. MethodsData were aggregated from...

Background: Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis...